Akari Therapeutics (NASDAQ:AKTX) Stock Passes Above 50-Day Moving Average – Here’s Why

Akari Therapeutics PLC (NASDAQ:AKTX)’s share price crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.26 and traded as high as $0.2773. Akari Therapeutics shares last traded at $0.2570, with a volume of 760,478 shares traded.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. LADENBURG THALM/SH SH assumed coverage on shares of Akari Therapeutics in a research note on Monday, January 5th. They issued a “buy” rating and a $1.00 price objective for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Akari Therapeutics in a research note on Wednesday, January 21st. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $2.53.

Akari Therapeutics Stock Performance

The business has a 50 day moving average of $0.26 and a two-hundred day moving average of $0.51.

Hedge Funds Weigh In On Akari Therapeutics

A hedge fund recently bought a new stake in Akari Therapeutics stock. Armistice Capital LLC purchased a new stake in Akari Therapeutics PLC (NASDAQ:AKTX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned 5.95% of Akari Therapeutics at the end of the most recent quarter. 5.06% of the stock is currently owned by institutional investors and hedge funds.

About Akari Therapeutics

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.